Purpose: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To explore whether proton beam therapy (PBT) can be an alternative to surgical resection in these patients, this study aimed to examine the retrospective treatment outcomes of patients with GGO-type lung cancer who underwent PBT.
Patients and methods: Patients with stage I NSCLC and GGOs who underwent PBT at the Medipolis Proton Therapy and Research Center (Kagoshima, Japan) between April 2011 and September 2015 were included. Patients were treated with a total dose of 66 GyE delivered in 10 fractions. Survival curves were calculated using the Kaplan-Meier method, and treatment-related adverse events (AEs) were assessed.
Results: A total of 48 patients (median age: 70.9 ± 9.2 years; men: 54.2%) were analyzed, among whom 53 tumors were observed. The 3-year overall survival rate after PBT was 91.7% (95% confidence interval [CI], 79.3-96.8%), the 3-year disease-free survival rate was 85.4% (95% CI: 71.8-92.8%), and the 3-year local control rate among 53 tumors was 92.5% (95% CI: 81.1-97.1%). During the 3-year follow-up period, 4 patients died, and 3 survived despite recurrence or metastasis. Common AEs were radiation pneumonitis (89.6%), rib fracture (27.1%), and cough (27.1%). None of the patients developed grade ≥3 treatment-related AEs.
Conclusion: The results of this study suggest that PBT may be a promising alternative for patients with GGO-type lung cancer when surgical resection is not feasible, with excellent survival outcomes and tolerable treatment-related AEs.
{"title":"Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer.","authors":"Ichiro Nagata, Takashi Ogino, Takeshi Arimura, Takashi Yoshiura","doi":"10.2147/LCTT.S270283","DOIUrl":"https://doi.org/10.2147/LCTT.S270283","url":null,"abstract":"<p><strong>Purpose: </strong>Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To explore whether proton beam therapy (PBT) can be an alternative to surgical resection in these patients, this study aimed to examine the retrospective treatment outcomes of patients with GGO-type lung cancer who underwent PBT.</p><p><strong>Patients and methods: </strong>Patients with stage I NSCLC and GGOs who underwent PBT at the Medipolis Proton Therapy and Research Center (Kagoshima, Japan) between April 2011 and September 2015 were included. Patients were treated with a total dose of 66 GyE delivered in 10 fractions. Survival curves were calculated using the Kaplan-Meier method, and treatment-related adverse events (AEs) were assessed.</p><p><strong>Results: </strong>A total of 48 patients (median age: 70.9 ± 9.2 years; men: 54.2%) were analyzed, among whom 53 tumors were observed. The 3-year overall survival rate after PBT was 91.7% (95% confidence interval [CI], 79.3-96.8%), the 3-year disease-free survival rate was 85.4% (95% CI: 71.8-92.8%), and the 3-year local control rate among 53 tumors was 92.5% (95% CI: 81.1-97.1%). During the 3-year follow-up period, 4 patients died, and 3 survived despite recurrence or metastasis. Common AEs were radiation pneumonitis (89.6%), rib fracture (27.1%), and cough (27.1%). None of the patients developed grade ≥3 treatment-related AEs.</p><p><strong>Conclusion: </strong>The results of this study suggest that PBT may be a promising alternative for patients with GGO-type lung cancer when surgical resection is not feasible, with excellent survival outcomes and tolerable treatment-related AEs.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S270283","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38643538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with non-small cell lung cancer and represent a major factor in treatment decisions, most notably in the advanced stages. Small molecule tyrosine kinase inhibitors (TKIs) that target the EGFR, such as erlotinib, gefitinib, icotinib, afatinib, dacomitinib and osimertinib, have all shown to be effective in this setting. Osimertinib, a third-generation EGFR TKI, is a favorable option, but almost all patients develop resistance at some time point. There are no effective treatment options for patients who progress on osimertinib, but ongoing trials will hopefully address this unmet need. The aim of this review is to provide a comprehensive review of the data with EGFR TKIs, management of the toxicities and the ongoing trials with this class of agents.
{"title":"A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity.","authors":"Chung-Shien Lee, Sandhya Sharma, Emily Miao, Cheryl Mensah, Kevin Sullivan, Nagashree Seetharamu","doi":"10.2147/LCTT.S258444","DOIUrl":"10.2147/LCTT.S258444","url":null,"abstract":"<p><p>Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with non-small cell lung cancer and represent a major factor in treatment decisions, most notably in the advanced stages. Small molecule tyrosine kinase inhibitors (TKIs) that target the EGFR, such as erlotinib, gefitinib, icotinib, afatinib, dacomitinib and osimertinib, have all shown to be effective in this setting. Osimertinib, a third-generation EGFR TKI, is a favorable option, but almost all patients develop resistance at some time point. There are no effective treatment options for patients who progress on osimertinib, but ongoing trials will hopefully address this unmet need. The aim of this review is to provide a comprehensive review of the data with EGFR TKIs, management of the toxicities and the ongoing trials with this class of agents.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2020-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S258444","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38643103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-07eCollection Date: 2020-01-01DOI: 10.2147/LCTT.S262822
Wang Yang, Naifei Chen, Lingyu Li, Xiao Chen, Xiangliang Liu, Yongfei Zhang, Jiuwei Cui
Purpose: Although EGFR-mutated patients generally do not benefit from checkpoint inhibitors (ICIs), some patients in the KEYNOTE-001 study consistently benefited from this treatment. This study investigated immune microenvironment characteristics to identify the subgroup of patients that may benefit from ICIs.
Materials and methods: Using data from The Cancer Genome Atlas Program (TCGA) and Cancer Proteome Atlas, TMB and protein level of PD-L1 were explored in the patients with EGFR mutations and wild-type patients. Different patterns of EGFR mutations (according to EGFR co-mutation with different downstream pathway genesets) were used to group EGFR mutation population. Estimated infiltration analyses were used to explore changes in the immune microenvironment.
Results: This study analyzed somatic mutation data from 1287 patients from five cohorts (TCGA, Broad, The Tumour Sequencing Project, Memorial Sloan Kettering Cancer Center, Catalogue Of Somatic Mutations In Cancer database). The probability of EGFR mutation was approximately 14.30% (184/1287) and the co-mutation rate was 11.41% (21/184) in patients with EGFR mutations. Glycosaminoglycan-related pathways were significantly upregulated in the EGFR mutant group. EGFR-mutated patients had lower TMB and PD-L1 protein levels than those in wild-type patients. Increase immature DCs infiltration and decreased NK CD56dim, T gamma delta, cytotoxic, and Th2 cell infiltration were the main immune changes in EGFR-mutated patients. Patients with EGFR-MAPK co-mutations had higher levels of TMB and PD-L1 protein expression. Meanwhile, the co-mutated patients had a similar immune microenvironment as that in wild-type patients.
Conclusion: In this study, we defined a subgroup of patients with EGFR-MAPK co-mutations. These co-mutated patients may benefit from ICI treatment.
目的:尽管表皮生长因子受体(EGFR)突变患者一般不会从检查点抑制剂(ICIs)中获益,但KEYNOTE-001研究中的一些患者却一直从这种治疗中获益。本研究调查了免疫微环境特征,以确定可能从 ICIs 中获益的患者亚群:利用癌症基因组图谱计划(TCGA)和癌症蛋白质组图谱的数据,探讨了表皮生长因子受体(EGFR)突变患者和野生型患者的TMB和PD-L1蛋白水平。表皮生长因子受体突变的不同模式(根据表皮生长因子受体与不同下游通路基因组的共突变)用于对表皮生长因子受体突变人群进行分组。估计浸润分析用于探讨免疫微环境的变化:本研究分析了来自5个队列(TCGA、Broad、肿瘤测序项目、纪念斯隆-凯特琳癌症中心、Catalogue Of Somatic Mutations In Cancer数据库)的1287名患者的体细胞突变数据。表皮生长因子受体突变的概率约为14.30%(184/1287),表皮生长因子受体突变患者的共突变率为11.41%(21/184)。在表皮生长因子受体突变组中,糖胺聚糖相关通路明显上调。与野生型患者相比,表皮生长因子受体突变患者的TMB和PD-L1蛋白水平较低。EGFR突变患者的主要免疫变化是未成熟DC浸润增加,NK CD56dim、T gamma delta、细胞毒性和Th2细胞浸润减少。EGFR-MAPK共突变患者的TMB和PD-L1蛋白表达水平较高。同时,共突变患者的免疫微环境与野生型患者相似:在这项研究中,我们定义了一个表皮生长因子受体-MAPK共突变患者亚群。这些共突变患者可能会从 ICI 治疗中获益。
{"title":"Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations.","authors":"Wang Yang, Naifei Chen, Lingyu Li, Xiao Chen, Xiangliang Liu, Yongfei Zhang, Jiuwei Cui","doi":"10.2147/LCTT.S262822","DOIUrl":"10.2147/LCTT.S262822","url":null,"abstract":"<p><strong>Purpose: </strong>Although <i>EGFR</i>-mutated patients generally do not benefit from checkpoint inhibitors (ICIs), some patients in the KEYNOTE-001 study consistently benefited from this treatment. This study investigated immune microenvironment characteristics to identify the subgroup of patients that may benefit from ICIs.</p><p><strong>Materials and methods: </strong>Using data from The Cancer Genome Atlas Program (TCGA) and Cancer Proteome Atlas, TMB and protein level of PD-L1 were explored in the patients with <i>EGFR</i> mutations and wild-type patients. Different patterns of <i>EGFR</i> mutations (according to EGFR co-mutation with different downstream pathway genesets) were used to group <i>EGFR</i> mutation population. Estimated infiltration analyses were used to explore changes in the immune microenvironment.</p><p><strong>Results: </strong>This study analyzed somatic mutation data from 1287 patients from five cohorts (TCGA, Broad, The Tumour Sequencing Project, Memorial Sloan Kettering Cancer Center, Catalogue Of Somatic Mutations In Cancer database). The probability of <i>EGFR</i> mutation was approximately 14.30% (184/1287) and the co-mutation rate was 11.41% (21/184) in patients with <i>EGFR</i> mutations. Glycosaminoglycan-related pathways were significantly upregulated in the <i>EGFR</i> mutant group. <i>EGFR</i>-mutated patients had lower TMB and PD-L1 protein levels than those in wild-type patients. Increase immature DCs infiltration and decreased NK CD56dim, T gamma delta, cytotoxic, and Th2 cell infiltration were the main immune changes in <i>EGFR</i>-mutated patients. Patients with <i>EGFR</i>-MAPK co-mutations had higher levels of TMB and PD-L1 protein expression. Meanwhile, the co-mutated patients had a similar immune microenvironment as that in wild-type patients.</p><p><strong>Conclusion: </strong>In this study, we defined a subgroup of patients with <i>EGFR</i>-MAPK co-mutations. These co-mutated patients may benefit from ICI treatment.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2020-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/77/55/lctt-11-59.PMC7490071.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38424614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: The effects of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events (irAEs). In patients with advanced non-small-cell lung cancer, who tested positive for programmed death-ligand 1 (PD-L1), pembrolizumab, an immune checkpoint inhibitor can be used as a treatment, and it was found to improve overall survival. However, there are only a few reports on the relationship between the therapeutic effects of pembrolizumab in patients with lung cancer and the irAEs of pembrolizumab. The purpose of this study was to determine the correlation between immune-related adverse events and the effects of pembrolizumab monotherapy in patients with non-small-cell lung cancer.
Patients and methods: From February 2017 to August 2019, we conducted a retrospective analysis of the effects of pembrolizumab treatment and immune-related adverse events in 94 patients with non-small-cell lung cancer treated with pembrolizumab only.
Results: In 63 cases, irAEs were observed. The most common irAE was rash. PD-L1 positivity ≥ 50% tended to cause irAEs. The median progression-free survival (PFS) rates with and without irAEs were 371 days (95% CI, 184-NR) and 67 days (95% CI, 51-87 days), respectively. In a multivariate analysis, irAEs and Eastern Cooperative Oncology Group performance status (PS) were the factors related to PFS.
Conclusion: In patients with lung cancer, who were treated with pembrolizumab monotherapy, the development of irAEs was likely indicative of the positive effects of pembrolizumab. This novel finding appears to be useful for clinicians who work with pembrolizumab for lung cancer treatment.
目的:免疫检查点抑制剂的作用已被报道与免疫相关不良事件(irAEs)有关。对于程序性死亡配体1 (PD-L1)检测呈阳性的晚期非小细胞肺癌患者,pembrolizumab(一种免疫检查点抑制剂)可以用作治疗,并且发现它可以提高总生存率。然而,关于派姆单抗在肺癌患者中的治疗效果与派姆单抗的irae之间关系的报道很少。本研究的目的是确定非小细胞肺癌患者的免疫相关不良事件与派姆单抗单药治疗效果之间的相关性。患者和方法:2017年2月至2019年8月,我们对94例仅接受派姆单抗治疗的非小细胞肺癌患者的派姆单抗治疗效果和免疫相关不良事件进行了回顾性分析。结果:63例患者出现irAEs。最常见的irAE是皮疹。PD-L1≥50%倾向于引起irae。有和没有irAEs的中位无进展生存期(PFS)分别为371天(95% CI, 184-NR)和67天(95% CI, 51-87天)。在多变量分析中,irAEs和Eastern Cooperative Oncology Group performance status (PS)是与PFS相关的因素。结论:在接受派姆单抗单药治疗的肺癌患者中,irae的发生可能表明派姆单抗的积极作用。这一新发现似乎对使用派姆单抗治疗肺癌的临床医生有用。
{"title":"Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer.","authors":"Susumu Noguchi, Keiichiro Suminaga, Takahiro Kaki, Hiroaki Kawachi, Akari Fukao, Satoshi Terashita, Sadao Horikawa, Tatsuyoshi Ikeue, Takakazu Sugita","doi":"10.2147/LCTT.S254146","DOIUrl":"https://doi.org/10.2147/LCTT.S254146","url":null,"abstract":"<p><strong>Purpose: </strong>The effects of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events (irAEs). In patients with advanced non-small-cell lung cancer, who tested positive for programmed death-ligand 1 (PD-L1), pembrolizumab, an immune checkpoint inhibitor can be used as a treatment, and it was found to improve overall survival. However, there are only a few reports on the relationship between the therapeutic effects of pembrolizumab in patients with lung cancer and the irAEs of pembrolizumab. The purpose of this study was to determine the correlation between immune-related adverse events and the effects of pembrolizumab monotherapy in patients with non-small-cell lung cancer.</p><p><strong>Patients and methods: </strong>From February 2017 to August 2019, we conducted a retrospective analysis of the effects of pembrolizumab treatment and immune-related adverse events in 94 patients with non-small-cell lung cancer treated with pembrolizumab only.</p><p><strong>Results: </strong>In 63 cases, irAEs were observed. The most common irAE was rash. PD-L1 positivity ≥ 50% tended to cause irAEs. The median progression-free survival (PFS) rates with and without irAEs were 371 days (95% CI, 184-NR) and 67 days (95% CI, 51-87 days), respectively. In a multivariate analysis, irAEs and Eastern Cooperative Oncology Group performance status (PS) were the factors related to PFS.</p><p><strong>Conclusion: </strong>In patients with lung cancer, who were treated with pembrolizumab monotherapy, the development of irAEs was likely indicative of the positive effects of pembrolizumab. This novel finding appears to be useful for clinicians who work with pembrolizumab for lung cancer treatment.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2020-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S254146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38238882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-07-08eCollection Date: 2020-01-01DOI: 10.2147/LCTT.S249928
Marta Peri, Nicola Fazio
Neuroendocrine tumors (NETs) of the lung are well-differentiated neuroendocrine neoplasms (NENs) with a heterogeneous clinical behaviour. Unlike gastroenteropancreatic NENs where therapeutic armamentarium clearly increased over the last decade, everolimus represented the only clinical practical innovation for lung NET patients over the last years. Therefore, for lung NETs, a multidisciplinary discussion within a dedicated team remains critical for an adequate decision-making. Although the main regulatory authorities considered the everolimus-related evidence is enough to approve the drug in advanced lung NETs, several clinical features deserve to be discussed. In this review, we systemically and critically analysed the main clinical studies including patients with advanced lung NETs receiving everolimus. Furthermore, we reported the biological and clinical background of everolimus in lung NET setting. The purpose of this review is to help clinical community to contextualize evidence and experience for a personalised use of this drug in clinical practice in the context of advanced lung NET patients.
{"title":"Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature.","authors":"Marta Peri, Nicola Fazio","doi":"10.2147/LCTT.S249928","DOIUrl":"https://doi.org/10.2147/LCTT.S249928","url":null,"abstract":"<p><p>Neuroendocrine tumors (NETs) of the lung are well-differentiated neuroendocrine neoplasms (NENs) with a heterogeneous clinical behaviour. Unlike gastroenteropancreatic NENs where therapeutic armamentarium clearly increased over the last decade, everolimus represented the only clinical practical innovation for lung NET patients over the last years. Therefore, for lung NETs, a multidisciplinary discussion within a dedicated team remains critical for an adequate decision-making. Although the main regulatory authorities considered the everolimus-related evidence is enough to approve the drug in advanced lung NETs, several clinical features deserve to be discussed. In this review, we systemically and critically analysed the main clinical studies including patients with advanced lung NETs receiving everolimus. Furthermore, we reported the biological and clinical background of everolimus in lung NET setting. The purpose of this review is to help clinical community to contextualize evidence and experience for a personalised use of this drug in clinical practice in the context of advanced lung NET patients.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2020-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S249928","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38229078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-17eCollection Date: 2020-01-01DOI: 10.2147/LCTT.S239675
Alexa B Schrock, Russell Madison, Mark Rosenzweig, Justin M Allen, Rachel L Erlich, Siao-Yi Wang, Tarek Chidiac, Vodur Suresh Reddy, Jonathan W Riess, Ahmet Ersin Yassa, Abdur Shakir, Vincent A Miller, Brian M Alexander, Jeffrey Venstrom, Kimberly McGregor, Siraj M Ali
Background: ALK fusions are targetable drivers in non-small-cell lung cancer (NSCLC). However, patients with NSCLC harboring ALK rearrangements without a fusion partner identified in DNA have also been shown to respond to ALK inhibitors. We aimed to characterize complex ALK variants that may predict sensitivity to multiple approved ALK inhibitors.
Methods: Comprehensive genomic profiling (CGP) of DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue or blood-based circulating tumor DNA was performed for 39,159 NSCLC patients during routine clinical care. For a subset of cases, RNA sequencing was performed, and prior ALK test results and clinical treatment information were collected from treating physicians.
Results: We queried the Foundation Medicine NSCLC database and identified ALK internal inversions, as well as internal deletions, as the sole ALK rearrangements in 6 (0.02%) and 3 (0.01%) of cases, respectively. In cases with ALK internal inversions, RNA testing identified an EML4-ALK fusion in 2/2 cases evaluated, and 3/3 patients treated with ALK inhibitors had durable responses. A single patient with an ALK internal deletion and clinical data available responded to multiple ALK inhibitors. RNA data available for a subset of non-NSCLC cases suggest that ALK internal deletions removing a portion of the N-terminus are drivers themselves and do not result in ALK fusions. Fluorescence in situ hybridization (FISH) results were inconsistent for both classes of DNA events.
Conclusion: Rare internal inversions of ALK appear to be indicative of ALK fusions, which can be detected in RNA, and response to ALK inhibitors in patients with NSCLC. In contrast, ALK internal deletions are not associated with ALK fusions in RNA but likely represent targetable drivers themselves. These data suggest that CGP of DNA should be supplemented with immunohistochemistry or RNA-based testing to further resolve these events and match patients to effective therapies.
{"title":"Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <i>ALK</i> Gene Have Durable Responses to ALK Kinase Inhibitors.","authors":"Alexa B Schrock, Russell Madison, Mark Rosenzweig, Justin M Allen, Rachel L Erlich, Siao-Yi Wang, Tarek Chidiac, Vodur Suresh Reddy, Jonathan W Riess, Ahmet Ersin Yassa, Abdur Shakir, Vincent A Miller, Brian M Alexander, Jeffrey Venstrom, Kimberly McGregor, Siraj M Ali","doi":"10.2147/LCTT.S239675","DOIUrl":"https://doi.org/10.2147/LCTT.S239675","url":null,"abstract":"<p><strong>Background: </strong><i>ALK</i> fusions are targetable drivers in non-small-cell lung cancer (NSCLC). However, patients with NSCLC harboring <i>ALK</i> rearrangements without a fusion partner identified in DNA have also been shown to respond to ALK inhibitors. We aimed to characterize complex <i>ALK</i> variants that may predict sensitivity to multiple approved ALK inhibitors.</p><p><strong>Methods: </strong>Comprehensive genomic profiling (CGP) of DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue or blood-based circulating tumor DNA was performed for 39,159 NSCLC patients during routine clinical care. For a subset of cases, RNA sequencing was performed, and prior ALK test results and clinical treatment information were collected from treating physicians.</p><p><strong>Results: </strong>We queried the Foundation Medicine NSCLC database and identified ALK internal inversions, as well as internal deletions, as the sole <i>ALK</i> rearrangements in 6 (0.02%) and 3 (0.01%) of cases, respectively. In cases with <i>ALK</i> internal inversions, RNA testing identified an <i>EML4-ALK</i> fusion in 2/2 cases evaluated, and 3/3 patients treated with ALK inhibitors had durable responses. A single patient with an <i>ALK</i> internal deletion and clinical data available responded to multiple ALK inhibitors. RNA data available for a subset of non-NSCLC cases suggest that <i>ALK</i> internal deletions removing a portion of the N-terminus are drivers themselves and do not result in <i>ALK</i> fusions. Fluorescence in situ hybridization (FISH) results were inconsistent for both classes of DNA events.</p><p><strong>Conclusion: </strong>Rare internal inversions of <i>ALK</i> appear to be indicative of <i>ALK</i> fusions, which can be detected in RNA, and response to ALK inhibitors in patients with NSCLC. In contrast, <i>ALK</i> internal deletions are not associated with <i>ALK</i> fusions in RNA but likely represent targetable drivers themselves. These data suggest that CGP of DNA should be supplemented with immunohistochemistry or RNA-based testing to further resolve these events and match patients to effective therapies.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2020-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S239675","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37901660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-02eCollection Date: 2020-01-01DOI: 10.2147/LCTT.S239223
Diego Kauffmann-Guerrero, Rudolf Maria Huber
Lung cancer is the leading cause of death of all cancer entities and small-cell lung cancer (SCLC) is the most malignant subtype. Despite good initial response to chemotherapy, many patients relapse early and success of second line treatment remains poor. For years, no relevant improvement of second line treatment has been achieved in the field of SCLC. Lurbinectedin, a novel RNA-polymerase II inhibitor has shown promising results in pretreated SCLC patients as single agent and in combination with other chemotherapeutic drugs leading to an orphan drug designation from the FDA. This article reviews the current data on this emerging substance and its impact on the treatment of SCLC.
{"title":"Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin.","authors":"Diego Kauffmann-Guerrero, Rudolf Maria Huber","doi":"10.2147/LCTT.S239223","DOIUrl":"https://doi.org/10.2147/LCTT.S239223","url":null,"abstract":"<p><p>Lung cancer is the leading cause of death of all cancer entities and small-cell lung cancer (SCLC) is the most malignant subtype. Despite good initial response to chemotherapy, many patients relapse early and success of second line treatment remains poor. For years, no relevant improvement of second line treatment has been achieved in the field of SCLC. Lurbinectedin, a novel RNA-polymerase II inhibitor has shown promising results in pretreated SCLC patients as single agent and in combination with other chemotherapeutic drugs leading to an orphan drug designation from the FDA. This article reviews the current data on this emerging substance and its impact on the treatment of SCLC.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2020-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S239223","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37747997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-24eCollection Date: 2020-01-01DOI: 10.2147/LCTT.S244366
Anurag Mehta, Mumtaz Saifi, Ullas Batra, M Suryavanshi, Kush Gupta
Background: The ROS1 gene is a member of the "sevenless" subfamily of tyrosine-kinase insulin-receptor genes. ROS1-fusion rearrangement causes constitutive downstream signal transduction, with an oncogenic role in non-small-cell lung carcinoma (NSCLC). Fortunately, crizotinib, an ALK1 tyrosine-kinase inhibitor, provides long-term disease control. The objective of this molecular epidemiological study was to estimate the frequency of ROS1 rearrangements and evaluate treatment outcomes with crizotinib therapy.
Methods: Patients with stage IV NSCLC adenocarcinoma histology were considered for this study. The study was conducted according to the ethical principles stated in the latest version of the Declaration of Helsinki and the applicable guidelines for good clinical practice. Clinical characteristics and treatment details were collected from patients' medical records.
Results: A total of 709 stage IV NSCLC adenocarcinoma patients were included in the study. There were 457 (64.46%) men and 252 (35.54%) women, with a median age of 60 years. ROS1-gene rearrangement was positive in 20 (2.82%) cases, 13 using Fluorescent In-Situ Hybridization (FISH), and two and five cases, respectively, using immunohistochemistry (IHC) and next-generation sequencing (NGS), followed by confirmation with FISH. Fourteen of the 20 patients with ROS1-gene rearrangement received crizotinib therapy, with an objective response rate of 64.28%. At a median follow-up of 6 months, the study had not achieved the end points of median progression free survival and overall survival.
Conclusion: ROS1-gene rearrangement was present at a relatively higher frequency of 2.8% in north Indian patients with lung adenocarcinoma and was successfully targeted by crizotinib therapy. Although the only US Food and Drug Administration and Conformité Européenne approved method for testing ROS1 rearrangement is NGS, FISH alone or IHC with D4D6 antibody as initial screen with subsequent confirmation of IHC-positive cases by FISH are cost-effective methods in institutions lacking NGS facilities.
背景:ROS1 基因是酪氨酸激酶胰岛素受体基因 "无七 "亚家族的成员。ROS1融合重排会导致构成性下游信号转导,在非小细胞肺癌(NSCLC)中具有致癌作用。幸运的是,ALK1 酪氨酸激酶抑制剂克唑替尼能长期控制病情。这项分子流行病学研究旨在估算ROS1重排的频率,并评估克唑替尼疗法的治疗效果:本研究考虑了组织学为 IV 期 NSCLC 腺癌的患者。研究按照最新版《赫尔辛基宣言》中规定的伦理原则和适用的良好临床实践指南进行。临床特征和治疗细节均从患者病历中收集:研究共纳入了 709 例 IV 期 NSCLC 腺癌患者。其中男性 457 例(64.46%),女性 252 例(35.54%),中位年龄为 60 岁。20例(2.82%)ROS1基因重排阳性,其中13例采用荧光原位杂交(FISH),2例和5例分别采用免疫组化(IHC)和下一代测序(NGS),然后用FISH确认。20例ROS1基因重排患者中有14例接受了克唑替尼治疗,客观反应率为64.28%。在中位随访6个月时,该研究未达到中位无进展生存期和总生存期的终点:结论:ROS1基因重排在北印度肺腺癌患者中出现的频率相对较高,为2.8%,克唑替尼疗法成功地靶向了这一基因重排。虽然美国食品药品管理局和欧洲合格评定委员会批准的唯一检测 ROS1 基因重排的方法是 NGS,但在缺乏 NGS 设备的机构中,仅用 FISH 或用 D4D6 抗体进行 IHC 初步筛查,然后用 FISH 确认 IHC 阳性病例是具有成本效益的方法。
{"title":"Incidence of <i>ROS1</i>-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients.","authors":"Anurag Mehta, Mumtaz Saifi, Ullas Batra, M Suryavanshi, Kush Gupta","doi":"10.2147/LCTT.S244366","DOIUrl":"10.2147/LCTT.S244366","url":null,"abstract":"<p><strong>Background: </strong>The <i>ROS1</i> gene is a member of the \"sevenless\" subfamily of tyrosine-kinase insulin-receptor genes. <i>ROS1</i>-fusion rearrangement causes constitutive downstream signal transduction, with an oncogenic role in non-small-cell lung carcinoma (NSCLC). Fortunately, crizotinib, an ALK1 tyrosine-kinase inhibitor, provides long-term disease control. The objective of this molecular epidemiological study was to estimate the frequency of <i>ROS1</i> rearrangements and evaluate treatment outcomes with crizotinib therapy.</p><p><strong>Methods: </strong>Patients with stage IV NSCLC adenocarcinoma histology were considered for this study. The study was conducted according to the ethical principles stated in the latest version of the Declaration of Helsinki and the applicable guidelines for good clinical practice. Clinical characteristics and treatment details were collected from patients' medical records.</p><p><strong>Results: </strong>A total of 709 stage IV NSCLC adenocarcinoma patients were included in the study. There were 457 (64.46%) men and 252 (35.54%) women, with a median age of 60 years. <i>ROS1</i>-gene rearrangement was positive in 20 (2.82%) cases, 13 using Fluorescent In-Situ Hybridization (FISH), and two and five cases, respectively, using immunohistochemistry (IHC) and next-generation sequencing (NGS), followed by confirmation with FISH. Fourteen of the 20 patients with <i>ROS1</i>-gene rearrangement received crizotinib therapy, with an objective response rate of 64.28%. At a median follow-up of 6 months, the study had not achieved the end points of median progression free survival and overall survival.</p><p><strong>Conclusion: </strong><i>ROS1</i>-gene rearrangement was present at a relatively higher frequency of 2.8% in north Indian patients with lung adenocarcinoma and was successfully targeted by crizotinib therapy. Although the only US Food and Drug Administration and Conformité Européenne approved method for testing <i>ROS1</i> rearrangement is NGS, FISH alone or IHC with D4D6 antibody as initial screen with subsequent confirmation of IHC-positive cases by FISH are cost-effective methods in institutions lacking NGS facilities.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2020-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/97/lctt-11-19.PMC7047993.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37726303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-14eCollection Date: 2020-01-01DOI: 10.2147/LCTT.S224991
Viola W Zhu, Misako Nagasaka, Takafumi Kubota, Kunil Raval, Natasha Robinette, Octavio Armas, Wajd Al-Holou, Sai-Hong Ignatius Ou
Central nervous system (CNS) metastasis carries a significant morbidity and mortality in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). Next-generation ALK tyrosine kinase inhibitors (TKIs) are highly CNS-penetrant and have demonstrated remarkable intracranial activity across clinical studies, and yet radiation remains the mainstay of treatment modality against CNS metastasis. We have previously reported alectinib can induce CNS radiation necrosis even after a remote history of radiation (7 years post-radiation). Lorlatinib is another potent next-generation ALK TKI that can overcome many ALK resistance mutations and has been shown to have excellent activity in patients with baseline CNS metastasis. Here we report two ALK-rearranged NSCLC patients who developed radiation necrosis shortly after initiating lorlatinib following progression on the sequential treatment of crizotinib, alectinib, and brigatinib. In both cases, radiation necrosis is evidenced by serial MRI images and histological examination of the resected CNS metastasis that had previously been radiated. Our cases highlight the importance of recognizing CNS radiation necrosis that may mimic disease progression in ALK-rearranged NSCLC treated with and potentially precipated by next-generation ALK TKIs.
{"title":"Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in <i>ALK</i>-Rearranged NSCLC: A Report of Two Cases.","authors":"Viola W Zhu, Misako Nagasaka, Takafumi Kubota, Kunil Raval, Natasha Robinette, Octavio Armas, Wajd Al-Holou, Sai-Hong Ignatius Ou","doi":"10.2147/LCTT.S224991","DOIUrl":"https://doi.org/10.2147/LCTT.S224991","url":null,"abstract":"<p><p>Central nervous system (CNS) metastasis carries a significant morbidity and mortality in anaplastic lymphoma kinase (<i>ALK</i>)-rearranged non-small cell lung cancer (NSCLC). Next-generation ALK tyrosine kinase inhibitors (TKIs) are highly CNS-penetrant and have demonstrated remarkable intracranial activity across clinical studies, and yet radiation remains the mainstay of treatment modality against CNS metastasis. We have previously reported alectinib can induce CNS radiation necrosis even after a remote history of radiation (7 years post-radiation). Lorlatinib is another potent next-generation ALK TKI that can overcome many <i>ALK</i> resistance mutations and has been shown to have excellent activity in patients with baseline CNS metastasis. Here we report two <i>ALK</i>-rearranged NSCLC patients who developed radiation necrosis shortly after initiating lorlatinib following progression on the sequential treatment of crizotinib, alectinib, and brigatinib. In both cases, radiation necrosis is evidenced by serial MRI images and histological examination of the resected CNS metastasis that had previously been radiated. Our cases highlight the importance of recognizing CNS radiation necrosis that may mimic disease progression in <i>ALK</i>-rearranged NSCLC treated with and potentially precipated by next-generation ALK TKIs.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2020-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/LCTT.S224991","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37612439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-08eCollection Date: 2020-01-01DOI: 10.2147/LCTT.S186843
Yuen Yee Cheng, Emma M Rath, Anthony Linton, Man Lee Yuen, Ken Takahashi, Kenneth Lee
Asbestos is a naturally occurring mineral consisting of extremely fine fibres that can become trapped in the lungs after inhalation. Occupational and environmental exposures to asbestos are linked to development of lung cancer and malignant mesothelioma, a cancer of the lining surrounding the lung. This review discusses the factors that are making asbestos-induced lung cancer a continuing problem, including the extensive historic use of asbestos and decades long latency between exposure and disease development. Genomic mutations of DNA nucleotides and gene rearrangements driving lung cancer are well-studied, with biomarkers and targeted therapies already in clinical use for some of these mutations. The genes involved in these mutation biomarkers and targeted therapies are also involved in epigenetic mechanisms and are discussed in this review as it is hoped that identification of epigenetic aberrations in these genes will enable the same gene biomarkers and targeted therapies to be used. Currently, understanding of how asbestos fibres trapped in the lungs leads to epigenetic changes and lung cancer is incomplete. It has been shown that oxidoreduction reactions on fibre surfaces generate reactive oxygen species (ROS) which in turn damage DNA, leading to genetic and epigenetic alterations that reduce the activity of tumour suppressor genes. Epigenetic DNA methylation changes associated with lung cancer are summarised in this review, and some of these changes will be due to asbestos exposure. So far, little research has been carried out to separate the asbestos driven epigenetic changes from those due to non-asbestos causes of lung cancer. Asbestos-associated lung cancers exhibit less methylation variability than lung cancers in general, and in a large proportion of samples variability has been found to be restricted to promoter regions. Epigenetic aberrations in cancer are proving to be promising biomarkers for diagnosing cancers. It is hoped that further understanding of epigenetic changes in lung cancer can result in useful asbestos-associated lung cancer biomarkers to guide treatment. Research is ongoing into the detection of lung cancer epigenetic alterations using non-invasive samples of blood and sputum. These efforts hold the promise of non-invasive cancer diagnosis in the future. Efforts to reverse epigenetic aberrations in lung cancer by epigenetic therapies are ongoing but have not yet yielded success.
石棉是一种天然矿物,由极其细小的纤维组成,吸入后会滞留在肺部。职业和环境暴露于石棉与肺癌和恶性间皮瘤(一种肺周围内膜的癌症)的发生有关。这篇综述讨论了使石棉诱发肺癌成为一个持续性问题的因素,包括石棉在历史上的广泛使用以及从接触石棉到发病之间长达数十年的潜伏期。对导致肺癌的 DNA 核苷酸基因组突变和基因重排已进行了深入研究,其中一些突变的生物标志物和靶向疗法已用于临床。这些突变生物标志物和靶向疗法所涉及的基因也参与了表观遗传学机制,本综述将对这些基因的表观遗传学畸变进行讨论,希望通过对这些基因畸变的鉴定,能够使用相同的基因生物标志物和靶向疗法。目前,人们对滞留在肺部的石棉纤维如何导致表观遗传变化和肺癌的认识还不全面。研究表明,纤维表面的氧化还原反应会产生活性氧(ROS),进而损伤 DNA,导致基因和表观遗传学改变,降低肿瘤抑制基因的活性。本综述总结了与肺癌有关的表观遗传 DNA 甲基化变化,其中一些变化是由于接触石棉所致。迄今为止,将石棉导致的表观遗传变化与非石棉导致的肺癌表观遗传变化区分开来的研究还很少。与一般肺癌相比,石棉相关肺癌表现出较少的甲基化变异,而且在很大一部分样本中,变异仅限于启动子区域。事实证明,癌症中的表观遗传畸变是很有希望的癌症诊断生物标志物。希望对肺癌表观遗传变化的进一步了解能够产生有用的石棉相关肺癌生物标志物,以指导治疗。利用非侵入性血液和痰液样本检测肺癌表观遗传变化的研究正在进行中。这些努力为未来的无创癌症诊断带来了希望。通过表观遗传疗法逆转肺癌表观遗传畸变的努力正在进行中,但尚未取得成功。
{"title":"The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer.","authors":"Yuen Yee Cheng, Emma M Rath, Anthony Linton, Man Lee Yuen, Ken Takahashi, Kenneth Lee","doi":"10.2147/LCTT.S186843","DOIUrl":"10.2147/LCTT.S186843","url":null,"abstract":"<p><p>Asbestos is a naturally occurring mineral consisting of extremely fine fibres that can become trapped in the lungs after inhalation. Occupational and environmental exposures to asbestos are linked to development of lung cancer and malignant mesothelioma, a cancer of the lining surrounding the lung. This review discusses the factors that are making asbestos-induced lung cancer a continuing problem, including the extensive historic use of asbestos and decades long latency between exposure and disease development. Genomic mutations of DNA nucleotides and gene rearrangements driving lung cancer are well-studied, with biomarkers and targeted therapies already in clinical use for some of these mutations. The genes involved in these mutation biomarkers and targeted therapies are also involved in epigenetic mechanisms and are discussed in this review as it is hoped that identification of epigenetic aberrations in these genes will enable the same gene biomarkers and targeted therapies to be used. Currently, understanding of how asbestos fibres trapped in the lungs leads to epigenetic changes and lung cancer is incomplete. It has been shown that oxidoreduction reactions on fibre surfaces generate reactive oxygen species (ROS) which in turn damage DNA, leading to genetic and epigenetic alterations that reduce the activity of tumour suppressor genes. Epigenetic DNA methylation changes associated with lung cancer are summarised in this review, and some of these changes will be due to asbestos exposure. So far, little research has been carried out to separate the asbestos driven epigenetic changes from those due to non-asbestos causes of lung cancer. Asbestos-associated lung cancers exhibit less methylation variability than lung cancers in general, and in a large proportion of samples variability has been found to be restricted to promoter regions. Epigenetic aberrations in cancer are proving to be promising biomarkers for diagnosing cancers. It is hoped that further understanding of epigenetic changes in lung cancer can result in useful asbestos-associated lung cancer biomarkers to guide treatment. Research is ongoing into the detection of lung cancer epigenetic alterations using non-invasive samples of blood and sputum. These efforts hold the promise of non-invasive cancer diagnosis in the future. Efforts to reverse epigenetic aberrations in lung cancer by epigenetic therapies are ongoing but have not yet yielded success.</p>","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2020-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/d3/lctt-11-1.PMC6955579.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37611377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}